Literature DB >> 27353034

Ofatumumab-associated acute respiratory manifestations: clinical characteristics and treatment.

Alice Bonanni1, Enrica Bertelli1, Andrea Moscatelli2, Elisabetta Lampugnani2, Monica Bodria1, Pietro Ravani3, Gian Marco Ghiggeri4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27353034      PMCID： PMC5137839          DOI： 10.1111/bcp.13029

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  8 in total

1.  Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20.

Authors:  Jiamu Du; Hui Yang; Yajun Guo; Jianping Ding
Journal:  Mol Immunol       Date:  2009-05-08       Impact factor: 4.407

2.  Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study.

Authors:  Per S Sorensen; Steen Lisby; Richard Grove; Frederick Derosier; Steve Shackelford; Eva Havrdova; Jelena Drulovic; Massimo Filippi
Journal:  Neurology       Date:  2014-01-22       Impact factor: 9.910

3.  Ofatumumab for rituximab-resistant nephrotic syndrome.

Authors:  Biswanath Basu
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

4.  Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma--a phase II trial.

Authors:  Michelle Furtado; Martin J S Dyer; Rod Johnson; Margie Berrow; Simon Rule
Journal:  Br J Haematol       Date:  2014-02-08       Impact factor: 6.998

5.  Ofatumumab-associated acute respiratory manifestations: clinical characteristics and treatment.

Authors:  Alice Bonanni; Enrica Bertelli; Andrea Moscatelli; Elisabetta Lampugnani; Monica Bodria; Pietro Ravani; Gian Marco Ghiggeri
Journal:  Br J Clin Pharmacol       Date:  2016-06-28       Impact factor: 4.335

Review 6.  Regulatory T cells and minimal change nephropathy: in the midst of a complex network.

Authors:  R Bertelli; A Bonanni; A Di Donato; M Cioni; P Ravani; G M Ghiggeri
Journal:  Clin Exp Immunol       Date:  2015-10-12       Impact factor: 4.330

7.  Low-dose ofatumumab for rituximab-resistant nephrotic syndrome.

Authors:  Alice Bonanni; Roberta Rossi; Corrado Murtas; Gian Marco Ghiggeri
Journal:  BMJ Case Rep       Date:  2015-09-16

8.  Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial.

Authors:  Peter C Taylor; Emilia Quattrocchi; Stephen Mallett; Regina Kurrasch; Jørgen Petersen; David J Chang
Journal:  Ann Rheum Dis       Date:  2011-08-22       Impact factor: 19.103
  8 in total
  5 in total

1.  Ofatumumab-associated acute respiratory manifestations: clinical characteristics and treatment.

Authors:  Alice Bonanni; Enrica Bertelli; Andrea Moscatelli; Elisabetta Lampugnani; Monica Bodria; Pietro Ravani; Gian Marco Ghiggeri
Journal:  Br J Clin Pharmacol       Date:  2016-06-28       Impact factor: 4.335

2.  Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.

Authors:  Alice Bonanni; Marta Calatroni; Matteo D'Alessandro; Sara Signa; Enrica Bertelli; Michela Cioni; Eddi Di Marco; Roberto Biassoni; Gianluca Caridi; Giulia Ingrasciotta; Roberta Bertelli; Armando Di Donato; Maurizio Bruschi; Alberto Canepa; Giorgio Piaggio; Pietro Ravani; Gian Marco Ghiggeri
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

3.  Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.

Authors:  Pietro Ravani; Alice Bonanni; Gian Marco Ghiggeri
Journal:  BMJ Open       Date:  2017-03-17       Impact factor: 2.692

4.  Ofatumumab-associated acute pneumonitis: Not new but still the first case.

Authors:  Alice Bonanni; Enrica Bertelli; Chiara Panicucci; Matteo D'Alessandro; Andrea Moscatelli; Elisabetta Lampugnani; Oliviero Sacco; Gian Michele Magnano; Pietro Ravani; Gian Marco Ghiggeri
Journal:  Pharmacol Res Perspect       Date:  2016-12-26

Review 5.  New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?

Authors:  Biswanath Basu; Andrea Angeletti; Bilkish Islam; Gian Marco Ghiggeri
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.